Akcea Therapeutics, Inc. (NASDAQ:AKCA) was founded in 2014 and is headquartered in Cambridge, Massachusetts, USA. It is a subsidiary of Ionis Pharmaceuticals, Inc. , with 30 full-time employees (3/31/2017), focusing on the development of lipids Drugs for the treatment of cardiometabolic diseases caused by the disease.
Akcea Therapeutics, Inc. (AKCA):
Akcea Therapeutics, Inc. is a late-stage biopharmaceutical company under Ionis Pharmaceuticals, Inc., focusing on the development and commercialization of therapeutic drugs for cardiometabolic diseases caused by lipid disorders in the United States and internationally. Akcea Therapeutics develops products including:
- Volanesorsen-has completed the Phase III clinical study for the treatment of familial chylomicronemia syndrome; in the phase III clinical study for the treatment of familial partial malnutrition.
- AKCEA-APO(a)-LRx-Phase IIb clinical study for the treatment of hyperlipoproteinemia has been completed.
- AKCEA-ANGPTL3-LRx——Phase I/II clinical studies for the treatment of various lipid disorders have been completed.
- AKCEA-APOCIII-LRx—Currently in a phase I/II clinical study for the treatment of cardiovascular diseases caused by high triglycerides.
Akcea Therapeutics has signed a strategic cooperation agreement with Novartis Pharma AG .
Akcea Therapeutics, Inc. (AKCA) investment:
Akcea Therapeutics, Inc. (NASDAQ:AKCA) was listed on Nasdaq on 7/14/2017 IPO, with an issue price of US$8, issuing 15.625 million shares, raising US$125 million, stock code: AKCA.